BAAM
TAK icon

Baker Avenue Asset Management’s Takeda Pharmaceutical TAK Stock Holding History

Baker Avenue Asset Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-51
Closed -$842 – 1756
2023
Q1 		$842 Buy
+51
New +$812 ﹤0.01% 1246

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Avenue Asset Management's TAK Position: Q2 2023 in Review

Baker Avenue Asset Management sold out of Takeda Pharmaceutical (TAK) in Q2 2023, closing a stake of 51 shares — an estimated $842 sold.

Baker Avenue Asset Management first reported a position in TAK in Q1 2023 and held it in 1 quarter. The position peaked at $842 in Q1 2023. 310 funds tracked by Wall St. Rank hold TAK as of Q2 2023.

  • Baker Avenue Asset Management reported no remaining Takeda Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 51 Takeda Pharmaceutical shares in Q2 2023, an estimated $842.
  • Baker Avenue Asset Management first reported a position in Takeda Pharmaceutical in Q1 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Takeda Pharmaceutical position peaked at $842 in Q1 2023.
  • 310 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2023.

Based on Baker Avenue Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.